DSM Pharmaceutical Products had lined up a client for its new biologics plant in Australia even ahead of it opening. But as it officially goes online, it has added yet another deal to the roster.
Australia is paying for Bristol-Myers Squibb's melanoma drug Yervoy. And Yervoy is expensive. So, Australian officials plan to monitor patients treated with it to see whether the drug lives up to its promise. It's an unusual move--and unprecedented in Australia.
Australian parents are able to refuse to vaccinate their children while still claiming benefits of up to AU$2,000 ($1,835) by registering as "conscientious objectors." With immunization rates falling below 50% in some parts of the country, Australian Prime Minister Kevin Rudd is trying to close the loophole.
GlaxoSmithKline is pretty proud of its rotacaps and its blow-fill-seal lines at its packaging plant in the Melbourne, Australia, suburb of Boronia. Its tablet line, not so much, and the drugmaker will eliminate that line and lay off about a third of the workforce at the facility.
Australia's Novotech has sold off a 30% stake to private equity firm Mercury Capital, planning to use the money to spread its reach across Asia.
Royal DSM in June will open a new biologics plant in Brisbane, the first custom mammalian-based biopharmaceutical manufacturing facility in Australia.
Medtronic ($MDT) must deal with an Australian safety advisory concerning some potential problems with its Paradigm insulin pumps.
A blood test to determine a patient's suicide risk may be within reach. Scientists at the University of New South Wales in Australia and colleagues in Sweden believe they've come up with a viable diagnostic biomarker: higher-than-normal levels of the neurotransmitter quinolinic acid.
On Feb. 15, Australian boys began receiving Gardasil as part of a $21 million program geared toward vaccinating 12- and 13-year-olds.
Researchers at Australia's University of Queensland have developed a vaccine-delivery system that dispenses with needle and syringe.